On-demand Webinar
Rethinking GLP-1 Strategy: New Approaches to Access, Cost, and Accountability
Webinar summary
GLP-1 medications have fundamentally reshaped the obesity treatment landscape—delivering unprecedented clinical results while introducing significant cost pressure for employers and health plans. As demand continues to surge, many organizations remain hesitant to expand coverage through traditional PBM-led approaches given the scale, cost, and long-term implications of these therapies.
Join Marsh and Vida Health for a timely discussion on how leading employers are evolving their GLP-1 strategy. This session will explore how organizations are navigating this moment—balancing the need to expand access with the imperative to manage cost and risk responsibly.
Panelists will examine the emergence of direct-to-employer (DTE) models that offer greater transparency, flexibility, and alignment between cost and outcomes. We’ll discuss how these approaches can complement existing benefit structures while enabling a more proactive, accountable strategy for GLP-1 management.
Key takeaways:
- What Employers Should Do Now: Practical steps to evaluate and evolve GLP-1 strategies in a rapidly changing market
- From Coverage to Strategy: Why GLP-1s require a more comprehensive approach than traditional benefit design alone
- Navigating Coverage Hesitation: Why many organizations are pausing or limiting coverage—and what’s needed to move forward confidently
- The Role of Direct-to-Employer (DTE): How alternative purchasing models can offer greater control, transparency, and flexibility
